<DOC>
	<DOCNO>NCT00510133</DOCNO>
	<brief_summary>This phase II study evaluate safety , feasibility efficacy immunotherapy GRNVAC1 patient AML .</brief_summary>
	<brief_title>A Study Active Immunotherapy With GRNVAC1 Patients With Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>This multicenter , open-label evaluation feasibility , safety immunotherapy patient AML complete clinical remission . Patients undergo leukapheresis prior shortly complete consolidation chemotherapy . Dendritic cell transfected messenger RNA encode human telomerase reverse transcriptase ( hTERT ) portion lysosome-associated membrane protein LAMP-1 ( LAMP ) , mature , aliquoted , cryopreserved . The final autologous vaccine product refer GRNVAC1 . Patients vaccinate weekly 6 week , `` rest '' 4 week , receive 6 boost injection , administer every week 12 week . Patients follow every 4 week Week 54 , every 3 month 1 year , every 6 month approximately 5 year first vaccination relapse/progression .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>AML first complete remission ( CR1 ) second complete remission ( CR2 ) CR1 &gt; /= 6 month Has complete least one cycle consolidation chemotherapy within past 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hepatic/renal function CR1 good risk cytogenetic feature [ ( 15 ; 17 ) , ( 8 ; 21 ) , inv ( 16 ) ( 16:16 ) ] Central nervous system leptomeningeal disease Allogeneic stem cell transplant plan expect Documented allergy penicillin betalactam antibiotic Active ongoing autoimmune disease Clinically significant pulmonary cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>